Every 424B that TuHURA Biosciences, Inc. (HURA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HURA filings page.
TuHURA Biosciences filed a prospectus supplement to sell up to $50,000,000 of its common stock through an at-the-market (ATM) offering under a Sales Agreement with H.C. Wainwright & Co., LLC. The Sales Agent will receive a 3.0% commission on gross sales. The company states proceeds are intended for working capital and general corporate purposes. The prospectus uses an assumed price of $1.79 per share (last reported sale on March 31, 2026) for illustrative dilution calculations and reports 59,336,104 shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. has filed a mixed shelf prospectus allowing it to offer and sell up to $250,000,000 of debt, common stock, preferred stock, warrants, subscription rights, units and purchase contracts over time. The prospectus also registers 9,321,545 shares of common stock for resale by existing investors, including 4,570,629 outstanding shares and 4,750,916 shares issuable upon warrant exercise; TuHURA will not receive proceeds from these stockholder resales. The company is a clinical-stage immuno-oncology business, led by its IFx platform and a Phase 3 trial of IFx-2.0 in Merkel cell carcinoma, and plans to investigate TBS-2025 in a Phase 2 trial in AML. TuHURA states that net proceeds from its own future offerings will be used for working capital, Kineta merger-related costs and to advance its IFx-2.0 and TBS-2025 programs.
TuHURA Biosciences filed a prospectus supplement for the proposed resale by selling stockholders of up to 4,570,629 shares of common stock and up to 4,750,916 shares issuable upon exercise of warrants. The supplement incorporates a new Current Report on Form 8‑K and must be read with the base prospectus. TuHURA’s common stock trades on Nasdaq as HURA; the last reported sale price on October 30, 2025 was $2.48 per share.
The attached 8‑K discloses a secured bridge loan facility of up to $3,000,000 entered on October 27, 2025. An initial $1,500,000 advance was funded, with an additional $1,500,000 available during a 30‑day period. The loan bears 3% per month interest, maturing on December 31, 2025 or 30 days after an equity financing with gross cash proceeds over $12,000,000. It is secured by a first‑priority perfected security interest in U.S. patents related to ImmuneFx. In connection with the initial advance, the lender received a warrant to purchase 65,217 shares at the Nasdaq Official Closing Price on the grant date; each such warrant is immediately exercisable and expires two years from issuance.